Protective effect of INI-0602, a gap junction inhibitor, on dopaminergic neurodegeneration of mice with unilateral 6-hydroxydopamine injection.
J Neural Transm (Vienna)
; 121(11): 1349-55, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-24744047
ABSTRACT
INI-0602, a novel gap junction hemichannel inhibitor, was administered to hemi-Parkinsonism mice generated by striatal 6-hydroxydopamine injection. INI-0602 prevented the toxic activation of microglia, such as the increased number of the activated form, enlargement of cell bodies and induction of proinflammatory cytokines, such as IL-1ß and TNFα, in the ipsilateral striatum. On the other hand, INI-0602 induced the expression of neurotrophic factors, such as brain-derived neurotrophic factor and NT-4/5, in the 6-hydroxydopamine-treated striatum. INI-0602 treatment blocked not only dopaminergic loss in both the striatum and substantia nigra, but also apomorphine-induced rotational behavior.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dopamina
/
Oxidopamina
/
Fármacos Neuroprotetores
/
Adrenérgicos
/
Doenças Neurodegenerativas
/
Compostos Heterocíclicos de 4 ou mais Anéis
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article